Probiotic-derived nano-particles in alcoholic liver disease
益生菌衍生的纳米颗粒治疗酒精性肝病
基本信息
- 批准号:10056416
- 负责人:
- 金额:$ 8.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-15 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAgonistAlcohol-Induced DisordersAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsAryl Hydrocarbon ReceptorBacteriaBacterial TranslocationBilophila wadsworthiaBiological MarkersCellsChronicClinicalDevelopmentDigestive System DisordersDiseaseEndocytosisEnvironmentEpithelialEpithelial CellsEvaluationExperimental ModelsFunctional disorderFutureGingerGrowthHomeostasisIntestinesLeadLiver diseasesMediatingMusNational Institute on Alcohol Abuse and AlcoholismNatural regenerationOutcomeOxidative StressPathogenicityPathway interactionsPatientsPlayPreventionPrevention therapyProbioticsProductionReceptor SignalingRoleSamplingSignal TransductionTestingTherapeutic EffectTight JunctionsTryptophanUp-Regulationalcohol abuse therapyalcohol exposurearyl hydrocarbon receptor ligandbaseclinical applicationdisorder preventiondysbiosisexosomegut colonizationgut microbesgut microbiotaimprovedinflammatory disease of the intestineinterleukin-22intestinal barrierintestinal epitheliumisletmetabolomicsmicrobialmouse modelnanoparticlenutritionorgan injurypathogenic bacteriaprebioticspreventprobiotic therapyprogramsprotective effecttranscytosis
项目摘要
Probiotics have been used to prevent/treat alcoholic liver disease (ALD). Live probiotics need to colonize the gut
to exert their function. Unfortunately, underlying disease states provide an unfavorable environment for probiotic
bacterial gut colonization, which diminishes probiotics’ function. In the last few years, we showed that LGG
culture supernatant (LGGs, without live bacteria) was effective in the prevention of ALD in experimental models
of acute and chronic alcohol exposure in mice. However, how LGG supernatant exerts its therapeutic effects is
not fully understood. Exosomes are nanoparticles (NPs) derived from cell endocytosis which act as transmitters
between cells. Recent studies show that bacteria, both Gram-negative and Gram-positive, produce NPs. The
NPs derived from “bad” bacteria have been demonstrated to be pathogenic. However, “good” bacteria-,
probiotics-derived NPs have not been studied. Our preliminary study showed that administration of LGG-derived
exosome-like NPs (LDNPs) effectively reversed ALD in the binge-on-chronic alcohol exposure mouse model,
suggesting that probiotic LGGs may exert its function through LDNPs in ALD. Administration of LDNPs markedly
increased intestinal AhR activity, IL-22, and regenerating islet-derived 3 (Reg3) β and γ expression, which play
a key role in maintaining gut microbiota homeostasis and preventing bacterial intestinal transcytosis. In addition,
LDNPs administration significantly increased intestinal epithelial cell (IEC) tight junctions and decreased
circulating LPS concentration associated with upregulation of intestinal Nrf2 signaling, which is known for
protecting intestinal barrier junctions against oxidative stress-induced damage by alcohol. Metabolomic analysis
revealed that LDNPs contain high levels of microbial metabolites of tryptophan, which are AhR ligands, indicating
LDNPs may activate intestinal AhR signaling. Furthermore, we demonstrated that ginger exosome-like
nanoparticles (GDNPs) are preferentially taken up by LGG, suggesting that GDNP may serve as a prebiotic to
enhance the effects of LGG. These preliminary studies provide the groundwork for our central hypothesis that,
by activating intestinal AhR-Nrf2 signaling, LDNPs increase intestinal expression of Il-22, Reg3 and tight
junctions, and modulate gut microbiota homeostasis and enhance intestinal barrier function, leading to the
suppression of ALD. We will test our hypothesis in following four specific aims: (1) Determine the role of bacteria-
derived NPs in ALD; (2) Define the mechanisms of the beneficial effects of LDNPs in ALD; (3) Determine whether
GDNPs treatment enhances LDNP production and AhR agonist enrichment that lead to improved effects of
LDNPs against ALD; and (4) Evaluate the intestinal AhR-Nrf2 signaling in alcoholic hepatitis patients treated with
LGG. Completion of this study is expected to significantly impact the development of LGG-based probiotic
therapeutics in the treatment of alcohol-associated liver diseases.
益生菌已被用于预防/治疗酒精性肝病(ALD)。活的益生菌需要在肠道中定居
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WENKE FENG其他文献
WENKE FENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WENKE FENG', 18)}}的其他基金
Cannabidiol as a treatment for alcoholic liver disease
大麻二酚治疗酒精性肝病
- 批准号:
10753729 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
LGG 衍生纳米颗粒在酒精相关性肝病中激活肠道 FXR
- 批准号:
10531712 - 财政年份:2022
- 资助金额:
$ 8.07万 - 项目类别:
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver disease
LGG 衍生纳米颗粒在酒精相关性肝病中激活肠道 FXR
- 批准号:
10794805 - 财政年份:2022
- 资助金额:
$ 8.07万 - 项目类别:
Probiotic-derived nano-particles in alcoholic liver disease
益生菌衍生的纳米颗粒治疗酒精性肝病
- 批准号:
10625858 - 财政年份:2016
- 资助金额:
$ 8.07万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
9325388 - 财政年份:2015
- 资助金额:
$ 8.07万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
10457385 - 财政年份:2015
- 资助金额:
$ 8.07万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
10250531 - 财政年份:2015
- 资助金额:
$ 8.07万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
9766984 - 财政年份:2015
- 资助金额:
$ 8.07万 - 项目类别:
Mechanisms of Probiotics in Alcoholic Liver Disease
益生菌治疗酒精性肝病的机制
- 批准号:
10794806 - 财政年份:2015
- 资助金额:
$ 8.07万 - 项目类别:
FGF21 and adipose lipolysis in alcoholic fatty liver
FGF21 与酒精性脂肪肝中的脂肪分解
- 批准号:
8702281 - 财政年份:2014
- 资助金额:
$ 8.07万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 8.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 8.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 8.07万 - 项目类别: